We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Nanogen Gains Access to Schizophrenia Markers
News

Nanogen Gains Access to Schizophrenia Markers

Nanogen Gains Access to Schizophrenia Markers
News

Nanogen Gains Access to Schizophrenia Markers

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Nanogen Gains Access to Schizophrenia Markers"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Nanogen, Inc. has announced that it has entered into an agreement whereby the company acquired rights to genetic markers related to schizophrenia and responses to antipsychotic therapies.

The agreement is between Nanogen and the Co-operative Research Centre for Diagnostics and Queensland University of Technology in Australia.

Nanogen plans to utilize the markers to create diagnostic tests for schizophrenia and related conditions. Some of these markers may also help predict adverse drug reactions and therefore guide therapeutic decision-making.

“Schizophrenia affects approximately one percent of the U.S. population, with an estimated cost to the health care system of $63 billion annually,” said David Ludvigson, Nanogen’s president and chief operating officer.

“Due to its complexity - schizophrenia, like many mental disorders, is believed to be caused by mutations in multiple genes - development of effective diagnostics and treatments is likely to require multiplexed analytic methods capable of examining multiple genes simultaneously,” Ludvigson continued.

Nanogen’s NanoChip® multiplexing platform was recently submitted for FDA 510(K) clearance, along with the company’s cystic fibrosis carrier screening test.

The genetic component of schizophrenia is thought to account for 65-80% of the disease risk. The markers acquired by Nanogen are in genes that have been linked to schizophrenia in a number of clinical studies.

Advertisement